This was an open-label ( blinded assessor ) , parallel-group , randomized controlled trial that included RA patients aged 18 to 65 years , not on MTX , and having active disease ( Disease Activity Score for 28 joints using 3 variables [ DAS28 ( 3 ) ] 5.1 ) .